UNSPSC 51263104: Alprenolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 877K5MQ27W, chemically known as 2-propanol, 1-(o-allylphenoxy)-3-(isopropylamino)- but generally known as alprenolol, which bears US NIH Compound Identifier 2119. Alprenolol most often comes in glucuronide and hydrochloride forms. European Medicines Agency schedules Alprenolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05371MIG.

UNSPSC 51263104 Alprenolol is a Commodity code that captures pharmaceutical products state and local health agencies procure for community health and emergency response initiatives. Recent solicitations show state and local buyers purchasing opioid-antagonist medications and related health-system products through direct procurement rather than through broader pharmaceutical distribution channels. Seminole County, Florida, is procuring 1,900 units of Naloxone annually alongside Safe Drug Deactivation Systems through competitive bidding to support community health initiatives with quarterly deliveries. The issuing bodies include county health departments and state health agencies; Seminole County and the Texas Health and Human Services Commission appear in the recent pipeline. The scope extends beyond simple pharmaceutical purchase to include delivery logistics, insurance and compliance certifications (drug-free workplace, E-Verify), and in some cases partnership with federal funding streams such as FEMA, which triggers additional Clean Air Act and Federal Water Pollution Control Act compliance obligations.

Recent activity concentrates in Florida and Texas. Seminole County released IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023 (note: the due date appears to be a historical artifact in the source and should be verified against current procurement systems). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer pharmacy programs that would bypass traditional pharmacy benefit managers and group purchasing organizations; this RFI does not represent a formal solicitation but signals the state's intent to explore alternative pharmaceutical procurement models. Neither opportunity identifies explicit set-asides or disadvantaged-enterprise restrictions. Contract terms for the Seminole County procurement include a two-year initial term with a one-year renewal option and a three-month probationary termination clause.